A Two-Year, Randomized, Double-Masked, Multicenter, Three-Arm Study Comparing the Efficacy and Safety of RTH258 Versus Aflibercept in Subjects With Neovascular Age-Related Macular Degeneration
Principal Investigator
David AlbianiOverview
Body Locations and Systems
Macular DegenerationClinicalTrials.gov#
NCT02307682Status
Closed for RecruitmentStudy Start/End
Jun 1, 2015 to Feb 28, 2018Locations
Vancouver CommunityName/Title
Aleksandra Kuzmanovic, Clinical Trial CoordinatorPhone
604-875-4253 Email Address
aleksandra.kuzmanovic@vch.caPurpose of Study
The purpose of this study is to compare RTH258 ophthalmic solution for intravitreal (IVT) injection at two dosage levels to aflibercept solution for IVT injection (2 mg) in subjects with untreated active choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD) in the study eye.
Eligibility
Visit ClinicalTrials.gov for more information.
Disclaimer
Study Coordinators and Research Nurses cannot give medical advice over the phone. Telephone numbers and email addresses are provided for obtaining additional information on specific clinical research trials only. If you have specific questions which require clinical expertise, please call your primary care physician.